A First-in-human Phase 1 Dose Escalation Study of SAR428926 in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2017
At a glance
- Drugs SAR 428926 (Primary)
- Indications Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sanofi
- 06 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2017 Planned End Date changed from 30 Dec 2019 to 20 Apr 2020.
- 11 Oct 2017 Planned primary completion date changed from 30 Dec 2019 to 20 Apr 2020.